| Predicate |
Object |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-426
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P19-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D277-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-095
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-426
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-10 |
| filingDate |
2001-07-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2004-11-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate |
2004-11-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
KR-100454767-B1 |
| titleOfInvention |
Use of 4-[(4-thiazolyl)phenoxy]alkoxy-benzamidine derivatives for treatment of osteoporosis |
| abstract |
The invention leukotriene -B 4 (Leukotriene-B 4; hereinafter "LTB-4" will be referred to as) receptor antagonists are known to have an effect of 4- {5- [4- (5-isopropyl represented by the general formula (I) of the -2-methyl-1,3-thiazol-4-yl) phenoxy] pentoxy} -benzamidine or N-hydroxy-4- {5- [4- (5-isopropyl-2-methyl- 1,3-thiazol-4-yl) phenoxy] pentoxy} -benzamidine as a prophylactic and therapeutic agent for osteoporosis.n n n [Formula 1]n n n n n n n n In which R is H or OH. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8242152-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-100705875-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8227496-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7662840-B2 |
| priorityDate |
2001-07-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |